For eight years, a patient in Brisbane, Australia, had severe, precisely localized pain in one thigh. Doctors found no lump or other visible feature to account for it. Examination and the usual soft tissue imaging turned up findings that were equivocal at best. A variety of treatments and multiple medications did nothing, and a run of specialist consultations across several disciplines got no further. The pain changed how the patient moved. Walking shifted to accommodate it, and ordinary daily activities became difficult. Then a scan performed for a completely unrelated health problem found the answer by accident. Fluorine-18 fluorodeoxyglucose positron emission tomography, better known as an FDG PET scan, picked up a lesion at the exact spot that hurt. It was a glomus tumor. Complete surgical excision followed, and the authors describe the result as a definitive cure. The case appears in the August issue of the journal Pain Management, published online in May, from a team at the University of Queensland and the Queen Elizabeth II Jubilee Hospital. Glomus tumors are benign growths that arise from the glomus body, a tiny arteriovenous structure in the skin that helps regulate temperature. A pathology review describes them as accounting for less than 2 percent of soft tissue tumors. Size has almost nothing to do with the symptoms. The classic presentation is a triad of severe pain out of all proportion to the lesion, pinpoint tenderness, and hypersensitivity to cold. Under a fingernail, where most of them turn up, that combination is recognizable enough that experienced clinicians spot it quickly. Elsewhere in the body, it is a different story. A tumor a few millimeters across, buried in thigh muscle with no visible skin change, produces a symptom pattern that looks a great deal like nerve pain, a muscle injury, or a chronic pain syndrome. There are bedside tests. Love's pinpoint test uses steady pressure from something small to reproduce the pain, and Hildreth's sign looks for relief after a tourniquet is applied above the lesion. Both work best when a clinician already suspects the diagnosis and knows where to press, which is precisely what does not happen when the tumor is nowhere near a fingernail. The assumption that glomus tumors are essentially a fingernail problem is part of why they get missed. A Mayo Clinic team reviewing two decades of extradigital cases concluded that tumors outside the digits are not a rare subgroup at all, and that misdiagnosis and delay are common. The delay in the literature is remarkably consistent. A BMJ Case Reports paper describing a strikingly similar case, a woman in her mid-50s with eight years of right thigh pain, notes that patients with extradigital glomus tumors typically live with symptoms for an average of seven years before curative surgery. It also cites research finding that extradigital tumors account for 63 percent of all glomus tumors, with 14 percent of those in the leg. Two more cases published this year make the same point in the lower limb. One man had endured 12 years of hip pain and another five years of knee pain with wasting of the quadriceps before surgery resolved both. A case series from La Paz University Hospital in Madrid gives a sense of the population involved. Reviewing pathology records spanning more than five decades, the hospital identified 64 patients with non-subungual glomus tumors, 44 men and 20 women, with a mean age of 55.8 years and a mean tumor size of 1 centimeter. Imaging is not always the rescue either. That same series notes that MRI sensitivity approaches 90 percent while specificity sits near 50 percent, with false negatives most likely in the smallest lesions. The authors published the case alongside a literature review, and the point they are making is about pattern recognition rather than technology. The PET scan was not ordered to hunt for a glomus tumor. It was ordered for something else and happened to cover the right piece of anatomy. That distinction matters, because PET is expensive, involves a radiotracer and radiation exposure, and is not a screening tool for chronic musculoskeletal pain. Nobody is suggesting it should become one. The clinically useful takeaway is narrower: a small, hypermetabolic focus that lines up exactly with where a patient says it hurts deserves a second look rather than a shrug. The standard workup for suspected extradigital glomus tumor remains focused ultrasound or MRI aimed precisely at the tender point, sometimes supported by local anesthetic injection to confirm the source. This is a single patient. One case cannot establish how often PET incidentally uncovers these tumors, and it cannot tell anyone with unexplained limb pain that a hidden tumor is the explanation. Most chronic pain has no such tidy answer. Anyone with pain that is severe, unchanged over years, and reproducible at one specific spot can reasonably ask a clinician whether a focal soft tissue lesion has been ruled out at that exact location. What is a glomus tumor? A benign growth arising from the glomus body, a small structure that helps regulate blood flow and temperature. Most are around a centimeter or smaller and are found under a fingernail. Why are they so painful? The pain is out of proportion to the size. The classic triad is intense localized pain, pinpoint tenderness, and sensitivity to cold. What does extradigital mean? It means the tumor sits somewhere other than the fingers or toes, such as the thigh, forearm, or knee. Those locations are much harder to recognize. How long do patients usually wait for a diagnosis? Published series report an average of roughly seven years of symptoms before curative surgery, with individual delays running much longer. Should people with chronic pain ask for a PET scan? No. PET involves radiation and is not a screening test for musculoskeletal pain. The usual workup is targeted ultrasound or MRI over the tender spot, and complete excision generally resolves symptoms once the tumor is found. Published by Medicaldaily.com